- The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. - Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Infectious diseases remain a major threat to health and health security in the EU and globally.
The conditions for qualifying. An eligibility check tests your details against each one.
At least 3 independent partners
Does your company qualify?
Give a few facts about your company and project, and see for each condition whether you meet it.
Eligibility checkGrant from URBAN PROSUMERS (EU-funded project) across the EU. Total budget €180,000. Applications until 30 September 2026.
- Complete Indicator Framework: A validated indicator framework of short-term actions, outcomes and long-term impacts, for both the ECS programme and the Chips for Europe Initiative, integr…
This topic is the first phase of a two-phase competitive structure supported by Horizon Europe, implemented via a Coordination and Support Action (CSA) in close collaboration with the Europ…
A check is an indication from the published conditions and the facts you give. Only the competent authority decides whether you are eligible.